Economics of Global Health and Infectious Diseases
Economics of Global Health and Infectious Diseases Unit
Health Equity
This research theme focuses on generating equity-informative evidence within health services research and policy analysis.
- Completed
Aversion to health inequality between socioeconomic, ethnic, and geographic groups: Evidence from Australia - Current
Equity-centred analysis of Australian’s Pharmaceutical Benefit Advisory Committee (PBAC) vaccine funding recommendations: a critical review of public summary documents - Current
Asia-Pacific Pneumococcal Disease Control in the Pneumococcal Conjugate Vaccine Era - Current
Impact of childhood pneumonia on the health and economic well-being of the household in Laos - Current
Global economic surplus of PCV - Current
Supporting Participatory Evidence Generation to Control Transmissible Diseases in Our Region Using Modelling (SPECTRUM) - Completed
Accounting for equity considerations in cost-effectiveness analysis: a systematic review of rotavirus vaccine in low- and middle-income countries
Economic Evaluation
Our unit conducts costing studies and economic evaluations alongside applied work, including model-and trial-based cost-effectiveness analyses and explores their integration with implementation studies.
- Current
Asia-Pacific Pneumococcal Disease Control in the Pneumococcal Conjugate Vaccine Era - Current
Global economic surplus of PCV - Current
Optimising the PCV Schedule for Immunisation Policy Making in Fiji - Current
Modelling the cost-effectiveness and budget impact of introducing malaria vaccination program in Burundi - Current
EDIVA - Efficacy and Demonstration of IntraVenous Iron for Anemia - Health Economic Substudy - Current
Lancet Hematology Commission on Anemia - Current
Supporting Participatory Evidence Generation to Control Transmissible Diseases in Our Region Using Modelling (SPECTRUM) - Current
Implementation of an Integrated Model of Chlamydia (MoCCA) - Completed
Benefits and safety of Iron supplementation with Malaria chemoprevention to children in Malawi (IRMA) – a randomized controlled trial - Current
Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent Rheumatic Heart Disease: A non-inferiority randomized trial (GOALIE) - Completed
Model-based cost-effectiveness of maternal influenza immunisation in low income countries and value of information analysis when considering broader health impact - Current
Feasibility of high daily dose short course primaquine after G6PD testing for the radical cure of Plasmodium vivax malaria - Current
Evaluating Zoonotic Malaria Transmission and Agricultural Land Use in Indonesia - Completed
Multi-Species Malaria Transmission Modelling to Inform Policy Decisions - Completed
Accounting for equity considerations in cost-effectiveness analysis: a systematic review of rotavirus vaccine in low- and middle-income countries
Capacity Building
Our unit has partnerships in a wide range of countries where we work to strengthen within-country health economic capacity, through training, development and support alongside and in addition to our research.
Health Technology Assessment (HTA)
Our unit works in collaboration with a range of national and international policymakers to inform the funding of vaccines, medicines and other health interventions. We are part of the Melbourne Health Technology and Value Assessment Collaborative (M-VAC).